Welcome to iPASy Technologies

Pioneering in Prostate Cancer Diagnostics

Our Vision

Based on a successful Ph.D. program, iPASy Technologies was established to proactively respond to translate our research into a tangible, clinical-grade diagnostic solution for prostate cancer.

Join iPASy Technologies at the forefront of reshaping the trajectory of prostate cancer diagnostics.

iPASy Technologies – Pioneering Precision in Prostate Cancer Diagnosis

Our Mission

At iPASy Technologies, our mission is to redefine the landscape of prostate cancer diagnostics and screening. Aligned with this objective, we have developed a pioneering glycobiomarker-based diagnostic procedure that not only addresses the limitations of existing methods but also introduces simplicity, cost-effectiveness, and greater reliability.

The Problem We Address

Prostate cancer is a formidable health concern, one in eight men will be diagnosed with prostate cancer in their lifetime. Current deficiency exhibiting diagnostic methods often results in unnecessary treatments due to elevated false-positive rates of the conventional serum PSA test. iPASy Technologies strategically addresses this critical challenge by introducing an innovative diagnostic paradigm to augment accuracy, thus mitigating the likelihood of misdiagnosis.

Our Solution

Introducing our revolutionary diagnostic kit with a properly engineered, non-invasive, urine-sample-based solution, this paradigm-shifting approach not only streamlines the diagnostic process but also yields comprehensive clinical insights, rendering redundant the need for additional tests.

Key Innovations

PSA N-Glycosylation Analysis

Distinguished by the analysis of asparagine-linked carbohydrates of PSA, our methodology provides an encompassing view of prostate cancer-related N-glycomic alterations within a single diagnostic assay.

Recombinant Antibodies

Leveraging on state-of-the-art recombinant antibody technology, our procedure cost-effectively ensures selectivity, thereby will be readily accessible even in third-world countries.

Ease of Use

Our test is designed for simplicity, eliminating the need for specialized/highly skilled operator personnel.

The Scientific Basis of the Technology

The iPASy approach is thoroughly outlined in the groundbreaking article recently published by our founders in Analytica Chimica Acta, 2021 Nov 1;1184:338892. Additionally, the crucial information of altered N-glycosylation of PSA in prostate cancer is a well-established fact supported by several highly ranked research articles published by leading authorities in the field:

  • Tobisawa et al. (Biochem Biophys Res Commun, 2014 Jun 13;448(4):390-6.)
  • O’Kennedy et al. (Nat Rev Urol, 2013 Feb;10(2):99-107.)
  • Peracaula et al. (Theranostics, 2016 May 24;6(8):1190-204.)

IP Status

We are pleased to announce that our novel diagnostic method has already received a positive assessment at the PCT preliminary examination stage (patent application number: WO2022263873A1).

Why Choose iPASy Technologies?

Embrace the future of prostate cancer diagnostics with iPASy Technologies, characterized by:

Mitigated False Positives

Positioned as an alternative against unnecessary interventions, our method significantly diminishes the incidence of false positives, averting unwarranted medical treatments.

Non-Invasive Methodology

Departing from invasive norms, our methodology employs non-invasively collected urine samples

Comprehensive Diagnostic Insight

Beyond mere disease detection, our diagnostic kit furnishes nuanced insights into the risk and aggressiveness of prostate cancer, making clinical decision-making easier.

About Us

Founded in early 2023, iPASy Technologies is a med-tech startup with a focused mission of advancing prostate cancer diagnostics. Our inception traces back to a successful Ph.D. program, driven by a commitment of transitioning groundbreaking research into practical diagnostic solutions.

Professor Andras Guttman is a distinguished researcher in the field of analytical chemistry, renowned for his outstanding contributions to glycomics and capillary electrophoresis. As a visionary leader he pioneered innovative techniques in the analysis of complex biological molecules, earning him international recognition. At iPASy Andras serves as the rock-solid scientific background, crucial to our success.
Andras Guttman,Senior scientist, founder
Andras Guttman
Dóra has graduated as a food and nutrition engineer and brings practical experience from her previous work in an analytical laboratory. There, she gained hands-on expertise in conducting analytical tests and accurately handling documentation within a regulated environment.
Dóra SzaboJunior developer
Dóra Szabó
With a summa cum laude PhD in chemistry and a solid background in chemical engineering, Gabor combines academic excellence with practical know-how. He acquired extensive international exposure in both science and business during his time at The Scripps Research California, Givaudan Zürich, and CEITEC Brno. With a remarkable ten-year track record in deep tech and med tech, he has held various positions, including project management and CTO roles.
Gabor JarvasCEO, founder
Gabor Jarvas
Zsuzsa ensures smooth operations of iPASy with finesse and precision. Her attention to detail ensures that every aspect of our organization runs like a well-oiled machine, from managing schedules to streamlining communication channels. With her proactive approach make a vibrant and cohesive work culture within our dynamic team.
Zsuzsa Jarvasadministration and back-office
Zsuzsa Jarvas
Balazs completed a PhD program in chemical and bioengineering and his thesis work laid the technological basis for iPASy. His background includes work in the pharmaceutical industry, where he served as a Quality Control (QC) Manager in a GMP environment. Balazs is well-versed in regulatory systems and has contributed significantly to drug product development and registration.
Balazs ReiderSenior developer, founder
Balazs Reider
Hajnalka holds a PhD in environmental chemistry with a solid chemical background. As a postdoctoral fellow at the Technical University of Denmark, he delved into the field of recombinant DNA technology. She uses her more than 20 years of domestic and international research experience in the field of genetic and protein engineering. Her research focuses on the development of self-assembling, specifically binding proteins and enzymes, as well as the use of directed evolution methods for sensory and diagnostic procedures. Head of the Bio-Nanosystems Laboratory at University of Pannonia
Hajnalka JankovicsSenior developer, founder
Hajnalka Jankovics
Professor Andras Guttman is a distinguished researcher in the field of analytical chemistry, renowned for his outstanding contributions to glycomics and capillary electrophoresis. As a visionary leader he pioneered innovative techniques in the analysis of complex biological molecules, earning him international recognition. At iPASy Andras serves as the rock-solid scientific background, crucial to our success.
Andras Guttman,Senior scientist, founder
Andras Guttman
Dóra has graduated as a food and nutrition engineer and brings practical experience from her previous work in an analytical laboratory. There, she gained hands-on expertise in conducting analytical tests and accurately handling documentation within a regulated environment.
Dóra SzaboJunior developer
Dóra Szabó
With a summa cum laude PhD in chemistry and a solid background in chemical engineering, Gabor combines academic excellence with practical know-how. He acquired extensive international exposure in both science and business during his time at The Scripps Research California, Givaudan Zürich, and CEITEC Brno. With a remarkable ten-year track record in deep tech and med tech, he has held various positions, including project management and CTO roles.
Gabor JarvasCEO, founder
Gabor Jarvas
Zsuzsa ensures smooth operations of iPASy with finesse and precision. Her attention to detail ensures that every aspect of our organization runs like a well-oiled machine, from managing schedules to streamlining communication channels. With her proactive approach make a vibrant and cohesive work culture within our dynamic team.
Zsuzsa Jarvasadministration and back-office
Zsuzsa Jarvas
Balazs completed a PhD program in chemical and bioengineering and his thesis work laid the technological basis for iPASy. His background includes work in the pharmaceutical industry, where he served as a Quality Control (QC) Manager in a GMP environment. Balazs is well-versed in regulatory systems and has contributed significantly to drug product development and registration.
Balazs ReiderSenior developer, founder
Balazs Reider
Hajnalka holds a PhD in environmental chemistry with a solid chemical background. As a postdoctoral fellow at the Technical University of Denmark, he delved into the field of recombinant DNA technology. She uses her more than 20 years of domestic and international research experience in the field of genetic and protein engineering. Her research focuses on the development of self-assembling, specifically binding proteins and enzymes, as well as the use of directed evolution methods for sensory and diagnostic procedures. Head of the Bio-Nanosystems Laboratory at University of Pannonia
Hajnalka JankovicsSenior developer, founder
Hajnalka Jankovics

© 2025 All Rights Reserved.